Literature DB >> 3261775

Phenotypic variation in the response to the human immunodeficiency virus among derivatives of the CEM T and WIL-2 B cell lines.

S Chaffee1, J M Leeds, T J Matthews, K J Weinhold, M Skinner, D P Bolognesi, M S Hershfield.   

Abstract

Derivatives of the CEM T and WIL-2 B cell lines showed striking diversity in their responses to the HTLV-IIIB strain of the human immunodeficiency virus (HIV). Several stable phenotypic patterns could be defined, based on whether cells were permissive (P+, P-) for virus production, were sensitive or insensitive to cytopathic effects after infection by free virus (C+, C-), and whether they underwent fusion on contact with virus-infected cells (F+, F-). Although expression of CD4 was essential for infection by HTLV-IIIB, very low levels were sufficient for productive infection of WIL-2 derivatives. Conversely, some CEM T cell lines that expressed ample CD4, and which were able to bind virus gp120 and undergo fusion, did not support productive infection by free virus. One nonpermissive, CD4+ derivative of CEM could bind gp120 but failed to undergo fusion, suggesting an alteration in some membrane protein other than CD4 that is essential for virus entry and HIV-induced cell fusion. The AA2 derivative of the WIL-2 cell line is also described, which is remarkably permissive for HIV replication and exquisitely sensitive to virus cytopathic effect. The panel of related cell lines with different host-virus phenotypes could be useful for more precisely defining steps in the infectious cycle of HIV, and for identifying host cell genes and gene products that determine the outcome of HIV infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3261775      PMCID: PMC2188999          DOI: 10.1084/jem.168.2.605

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  46 in total

1.  Detection of HIV-1 neutralizing antibodies by a simple, rapid, colorimetric assay.

Authors:  A J Langlois; T J Matthews; K J Weinhold; S Chaffee; M Hershfield; D P Bolognesi
Journal:  AIDS Res Hum Retroviruses       Date:  1988-02       Impact factor: 2.205

2.  Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.

Authors:  M Kowalski; J Potz; L Basiripour; T Dorfman; W C Goh; E Terwilliger; A Dayton; C Rosen; W Haseltine; J Sodroski
Journal:  Science       Date:  1987-09-11       Impact factor: 47.728

3.  Human lymphoblastoid lines from lymph node and spleen.

Authors:  J A Levy; M Virolainen; V Defendi
Journal:  Cancer       Date:  1968-09       Impact factor: 6.860

4.  A biochemical genetic study of the role of specific nucleoside kinases in deoxyadenosine phosphorylation by cultured human cells.

Authors:  B Ullman; B B Levinson; M S Hershfield; D W Martin
Journal:  J Biol Chem       Date:  1981-01-25       Impact factor: 5.157

5.  Patterns of antigenic expression on human monocytes as defined by monoclonal antibodies.

Authors:  M A Talle; P E Rao; E Westberg; N Allegar; M Makowski; R S Mittler; G Goldstein
Journal:  Cell Immunol       Date:  1983-05       Impact factor: 4.868

6.  Effects of mutational loss of adenosine kinase and deoxycytidine kinase on deoxyATP accumulation and deoxyadenosine toxicity in cultured CEM human T-lymphoblastoid cells.

Authors:  M S Hershfield; J E Fetter; W C Small; A S Bagnara; S R Williams; B Ullman; D W Martin; D B Wasson; D A Carson
Journal:  J Biol Chem       Date:  1982-06-10       Impact factor: 5.157

7.  Differences in metabolism and cytotoxicity between 9-beta-D arabinofuranosyladenine and 9-beta-D-arabinofuranosyl-2-fluoroadenine in human leukemic lymphoblasts.

Authors:  L W Dow; D E Bell; L Poulakos; A Fridland
Journal:  Cancer Res       Date:  1980-05       Impact factor: 12.701

8.  Regulation of de novo purine biosynthesis in human lymphoblasts. Coordinate control of proximal (rate-determining) steps and the inosinic acid branch point.

Authors:  M S Hershfield; J E Seegmiller
Journal:  J Biol Chem       Date:  1976-12-10       Impact factor: 5.157

9.  Adenine and adenosine are toxic to human lymphoblast mutants defective in purine salvage enzymes.

Authors:  M S Hershfield; F F Snyder; J E Seegmiller
Journal:  Science       Date:  1977-09-23       Impact factor: 47.728

10.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  15 in total

1.  Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost.

Authors:  R J Gorelick; R E Benveniste; J D Lifson; J L Yovandich; W R Morton; L Kuller; B M Flynn; B A Fisher; J L Rossio; M Piatak; J W Bess; L E Henderson; L O Arthur
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins.

Authors:  J L Rossio; M T Esser; K Suryanarayana; D K Schneider; J W Bess; G M Vasquez; T A Wiltrout; E Chertova; M K Grimes; Q Sattentau; L O Arthur; L E Henderson; J D Lifson
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

3.  Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment.

Authors:  J D Lifson; J L Rossio; R Arnaout; L Li; T L Parks; D K Schneider; R F Kiser; V J Coalter; G Walsh; R J Imming; B Fisher; B M Flynn; N Bischofberger; M Piatak; V M Hirsch; M A Nowak; D Wodarz
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

4.  Effect of a single amino acid substitution in the V3 domain of the human immunodeficiency virus type 1: generation of revertant viruses to overcome defects in infectivity in specific cell types.

Authors:  J F Morris; E J Sternberg; L Gutshall; S R Petteway; L A Ivanoff
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

5.  Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.

Authors:  M T Esser; T Mori; I Mondor; Q J Sattentau; B Dey; E A Berger; M R Boyd; J D Lifson
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

6.  An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity.

Authors:  J Konvalinka; M A Litterst; R Welker; H Kottler; F Rippmann; A M Heuser; H G Kräusslich
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.

Authors:  T Muster; F Steindl; M Purtscher; A Trkola; A Klima; G Himmler; F Rüker; H Katinger
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

8.  Antiretroviral activities of protease inhibitors against murine leukemia virus and simian immunodeficiency virus in tissue culture.

Authors:  P L Black; M B Downs; M G Lewis; M A Ussery; G B Dreyer; S R Petteway; D M Lambert
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

9.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.

Authors:  A Trkola; M Purtscher; T Muster; C Ballaun; A Buchacher; N Sullivan; K Srinivasan; J Sodroski; J P Moore; H Katinger
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

10.  Human immunodeficiency viruses containing heterologous enhancer/promoters are replication competent and exhibit different lymphocyte tropisms.

Authors:  L J Chang; E McNulty; M Martin
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.